-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD) Declines By 57.8%
Short Interest in Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD) Declines By 57.8%
Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD – Get Rating) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 1,900 shares, a decrease of 57.8% from the August 15th total of 4,500 shares. Based on an average trading volume of 43,500 shares, the short-interest ratio is currently 0.0 days.
Institutional Trading of Intelligent Medicine Acquisition
Hedge funds have recently bought and sold shares of the business. Centiva Capital LP increased its holdings in shares of Intelligent Medicine Acquisition by 45.6% during the 2nd quarter. Centiva Capital LP now owns 43,535 shares of the company's stock worth $436,000 after buying an additional 13,644 shares during the last quarter. Aristeia Capital LLC increased its holdings in shares of Intelligent Medicine Acquisition by 67.6% during the 2nd quarter. Aristeia Capital LLC now owns 419,000 shares of the company's stock worth $4,198,000 after buying an additional 169,000 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Intelligent Medicine Acquisition by 14.6% during the 2nd quarter. Woodline Partners LP now owns 28,650 shares of the company's stock worth $287,000 after buying an additional 3,650 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Intelligent Medicine Acquisition by 2.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 439,530 shares of the company's stock worth $4,404,000 after buying an additional 12,288 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Intelligent Medicine Acquisition during the 2nd quarter worth approximately $2,647,000. Institutional investors and hedge funds own 55.04% of the company's stock.
Get Intelligent Medicine Acquisition alerts:Intelligent Medicine Acquisition Stock Performance
IQMD stock remained flat at $10.04 during mid-day trading on Wednesday. 2,747 shares of the company's stock were exchanged, compared to its average volume of 41,796. Intelligent Medicine Acquisition has a 12 month low of $9.86 and a 12 month high of $10.93. The company's fifty day moving average price is $10.04 and its 200 day moving average price is $10.01.
Intelligent Medicine Acquisition Company Profile
(Get Rating)Intelligent Medicine Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of life science.
See Also
- Get a free copy of the StockNews.com research report on Intelligent Medicine Acquisition (IQMD)
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Four Cheap Stocks With Interesting Insider Activity
- Is Five Below Trying to Punch Too High?
Receive News & Ratings for Intelligent Medicine Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Medicine Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD – Get Rating) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 1,900 shares, a decrease of 57.8% from the August 15th total of 4,500 shares. Based on an average trading volume of 43,500 shares, the short-interest ratio is currently 0.0 days.
智能医药收购公司(纳斯达克代码:IQMD-GET Rating)8月份空头股数销量大幅下降。截至8月31日,空头股数共有1900股,比8月15日的4500股减少了57.8%。以平均成交量43,500股计算,目前短息比率为0.0天。
Institutional Trading of Intelligent Medicine Acquisition
智能医药收购的制度性交易
Hedge funds have recently bought and sold shares of the business. Centiva Capital LP increased its holdings in shares of Intelligent Medicine Acquisition by 45.6% during the 2nd quarter. Centiva Capital LP now owns 43,535 shares of the company's stock worth $436,000 after buying an additional 13,644 shares during the last quarter. Aristeia Capital LLC increased its holdings in shares of Intelligent Medicine Acquisition by 67.6% during the 2nd quarter. Aristeia Capital LLC now owns 419,000 shares of the company's stock worth $4,198,000 after buying an additional 169,000 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Intelligent Medicine Acquisition by 14.6% during the 2nd quarter. Woodline Partners LP now owns 28,650 shares of the company's stock worth $287,000 after buying an additional 3,650 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Intelligent Medicine Acquisition by 2.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 439,530 shares of the company's stock worth $4,404,000 after buying an additional 12,288 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Intelligent Medicine Acquisition during the 2nd quarter worth approximately $2,647,000. Institutional investors and hedge funds own 55.04% of the company's stock.
对冲基金最近买卖了该公司的股票。Centiva Capital LP在第二季度增持了智能医药收购的股票45.6%。Centiva Capital LP现在拥有43,535股该公司股票,价值436,000美元,上个季度又购买了13,644股。Aristeia Capital LLC在第二季度增持了智能医药收购的股票67.6%。Aristeia Capital LLC现在拥有419,000股该公司股票,价值4,19.8万美元,在上个季度又购买了169,000股。Woodline Partners LP在第二季度增持了智能医药收购的股份14.6%。Woodline Partners LP现在拥有28,650股该公司股票,价值28.7万美元,上个季度又购买了3,650股。Cubist Systems Strategy LLC在第二季度增持了智能医疗收购的股份2.9%。Cubist Systems Strategy LLC在上个季度额外购买了12,288股后,现在拥有439,530股该公司股票,价值4,404,000美元。最后,Millennium Management LLC在第二季度收购了智能医药收购公司的新股份,价值约2,647,000美元。机构投资者和对冲基金持有该公司55.04%的股票。
Intelligent Medicine Acquisition Stock Performance
智能医药收购股票表现
IQMD stock remained flat at $10.04 during mid-day trading on Wednesday. 2,747 shares of the company's stock were exchanged, compared to its average volume of 41,796. Intelligent Medicine Acquisition has a 12 month low of $9.86 and a 12 month high of $10.93. The company's fifty day moving average price is $10.04 and its 200 day moving average price is $10.01.
周三午盘,IQMD股价持平于10.04美元。该公司股票成交量为2,747股,而其平均成交量为41,796股。智能医药收购的12个月低点为9.86美元,12个月高位为10.93美元。该公司的50日移动均线价格为10.04美元,200日移动均线价格为10.01美元。
Intelligent Medicine Acquisition Company Profile
智能医药收购公司简介
Intelligent Medicine Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of life science.
智能医药收购公司没有重大业务。公司专注于与一家或多家企业进行合并、资本换股、资产收购、股票购买、重组或相关业务合并。它打算确定生命科学领域的商业机会。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Intelligent Medicine Acquisition (IQMD)
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Four Cheap Stocks With Interesting Insider Activity
- Is Five Below Trying to Punch Too High?
- 免费获取StockNews.com关于智能医学获取(IQMD)的研究报告
- 随着收购传言的甚嚣尘上,Lyft能否成功?
- 健康饮料制造商Celsius能否超越其Monster竞争对手?
- 现在是时候接受标准普尔500指数再下跌25%的时候了
- 具有有趣内幕活动的四只廉价股票
- 下面的五个是不是打得太高了?
Receive News & Ratings for Intelligent Medicine Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intelligent Medicine Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
接受《智能医药采购日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对智能医药收购和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧